ResMed Inc. $RMD Shares Sold by Sumitomo Mitsui Trust Group Inc.

Posted by Don Miller on Jul 12th, 2026

Sumitomo Mitsui Trust Group Inc. cut its holdings in ResMed Inc. (NYSE:RMD – Free Report) by 5.5% in the first quarter, according to the company in its most recent disclosure with the SEC. The fund owned 345,620 shares of the medical equipment provider’s stock after selling 19,932 shares during the quarter. Sumitomo Mitsui Trust Group Inc.’s holdings in ResMed were worth $77,585,000 at the end of the most recent reporting period.

Several other institutional investors have also added to or reduced their stakes in the business. Hsbc Holdings PLC increased its stake in ResMed by 17.6% during the 4th quarter. Hsbc Holdings PLC now owns 328,785 shares of the medical equipment provider’s stock valued at $79,321,000 after purchasing an additional 49,253 shares in the last quarter. Nordea Investment Management AB boosted its position in ResMed by 37.2% in the fourth quarter. Nordea Investment Management AB now owns 1,084,996 shares of the medical equipment provider’s stock valued at $262,027,000 after buying an additional 294,124 shares during the last quarter. Goldman Sachs Group Inc. boosted its position in ResMed by 13.7% in the fourth quarter. Goldman Sachs Group Inc. now owns 979,087 shares of the medical equipment provider’s stock valued at $235,833,000 after buying an additional 118,296 shares during the last quarter. Fideuram Asset Management Ireland dac acquired a new position in ResMed in the 4th quarter worth approximately $4,712,000. Finally, Legal & General Group Plc increased its holdings in ResMed by 3.6% in the 4th quarter. Legal & General Group Plc now owns 992,527 shares of the medical equipment provider’s stock worth $239,070,000 after buying an additional 34,317 shares during the period. Institutional investors and hedge funds own 54.98% of the company’s stock.

ResMed Price Performance

ResMed stock traded down $4.28 during trading on Friday, reaching $204.17. The company had a trading volume of 1,331,127 shares, compared to its average volume of 1,566,866. The firm has a market capitalization of $29.62 billion, a PE ratio of 19.69, a price-to-earnings-growth ratio of 1.22 and a beta of 0.78. The firm’s 50-day simple moving average is $200.46 and its 200 day simple moving average is $228.27. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.33 and a current ratio of 3.01. ResMed Inc. has a 1-year low of $180.26 and a 1-year high of $293.81.

ResMed (NYSE:RMD – Get Free Report) last posted its quarterly earnings data on Thursday, April 30th. The medical equipment provider reported $2.86 earnings per share for the quarter, topping analysts’ consensus estimates of $2.79 by $0.07. The company had revenue of $1.43 billion during the quarter, compared to analysts’ expectations of $1.42 billion. ResMed had a net margin of 27.44% and a return on equity of 25.35%. The firm’s revenue for the quarter was up 10.8% on a year-over-year basis. During the same period in the prior year, the business posted $2.37 earnings per share. As a group, equities research analysts anticipate that ResMed Inc. will post 11.13 earnings per share for the current fiscal year.

ResMed Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Thursday, June 18th. Stockholders of record on Thursday, May 14th were paid a dividend of $0.60 per share. The ex-dividend date of this dividend was Thursday, May 14th. This represents a $2.40 dividend on an annualized basis and a dividend yield of 1.2%. ResMed’s payout ratio is currently 23.14%.

ResMed News Summary

Here are the key news stories impacting ResMed this week:

Positive Sentiment: ResMed’s sale of MatrixCare should simplify the portfolio, increase focus on higher-growth core franchises, and potentially improve capital allocation. Resmed Divests MatrixCare Business to Sharpen Focus on Connected Care
Positive Sentiment: Analyst commentary has described the transaction as a “portfolio reset,” which suggests the market may view the move as strategically constructive for long-term growth. ResMed (RMD) Sells MatrixCare To Refocus On Sleep And Respiratory Health
Positive Sentiment: Brokerage coverage remained supportive, with multiple firms reiterating buy-type ratings, reinforcing confidence in ResMed’s core business despite the divestiture. Resmed Inc CHESS Depositary Interests … Gets a Buy from Morgans
Neutral Sentiment: Unusually large put-option activity suggests some traders are hedging or betting on downside, but it does not confirm a change in the company’s fundamentals.
Neutral Sentiment: CEO Michael Farrell’s recent stock sale was made under a pre-arranged 10b5-1 plan, making it more routine than a clear bearish signal, though insider selling can still weigh on sentiment. Insider Selling: ResMed (NYSE:RMD) CEO Sells $1,090,783.05 in Stock

Wall Street Analysts Forecast Growth

Several analysts have recently commented on RMD shares. Jefferies Financial Group dropped their price objective on shares of ResMed from $240.00 to $225.00 and set a “hold” rating on the stock in a report on Friday. Evercore set a $255.00 price target on ResMed and gave the company an “outperform” rating in a report on Monday, April 13th. Wall Street Zen lowered shares of ResMed from a “buy” rating to a “hold” rating in a research report on Saturday, March 14th. Weiss Ratings lowered shares of ResMed from a “hold (c+)” rating to a “hold (c)” rating in a research note on Friday, May 22nd. Finally, The Goldman Sachs Group restated a “buy” rating on shares of ResMed in a research note on Wednesday, July 1st. One investment analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating and seven have assigned a Hold rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $263.08.

View Our Latest Stock Report on ResMed

Insider Buying and Selling at ResMed

In related news, CEO Michael J. Farrell sold 4,991 shares of the company’s stock in a transaction dated Tuesday, July 7th. The shares were sold at an average price of $218.55, for a total transaction of $1,090,783.05. Following the completion of the transaction, the chief executive officer owned 466,223 shares in the company, valued at $101,893,036.65. This represents a 1.06% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders have sold 14,973 shares of company stock worth $3,096,067. 0.65% of the stock is owned by corporate insiders.

ResMed Profile

(Free Report)

ResMed (NYSE: RMD) is a global medical device and cloud-connectivity company focused on improving outcomes for people with sleep-disordered breathing and chronic respiratory conditions. Founded in 1989, the company is headquartered in San Diego, California, and develops, manufactures and distributes a range of devices and software used by patients, clinicians and providers worldwide.

ResMed’s product portfolio centers on noninvasive ventilation and sleep therapy equipment, including continuous positive airway pressure (CPAP) and bilevel devices, masks and related accessories for the treatment of obstructive sleep apnea and other respiratory disorders.